Immune response and adverse events after vaccination against SARS‐CoV‐2 in adult patients with transfusion‐dependent thalassaemia. (14th March 2022)

• Record Type: Journal Article
• Authors: Delaporta, Polyxeni; Terpos, Evangelos; Solomou, Elena E.; Gumeni, Sentiljana; Nitsa, Evangelia; Apostolakou, Filia; Kyriakopoulou, Dimitra; Ntanasis‐Stathopoulos, Ioannis; Papassotiriou, Ioannis; Trougakos, Ioannis P.; Dimopoulos, Meletios A.; Kattamis, Antonis
• Is Part Of: British journal of haematology. Volume 197:Number 5(2022)
• Page Start: 576
• Page End: 579
• Publication Date: 2022-03-14
• Subjects: coronavirus disease 2019 (COVID‐19) -- thalassaemia -- vaccines; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18146
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Patients with transfusion‐dependent thalassaemia (TDT) are considered an at increased‐risk population for severe and/or morbid coronavirus disease 2019 (COVID‐19) infection. Timely vaccination is the main preventive method for severe COVID‐19. Different adverse events and reactions after vaccination have been reported, with severe ones being extremely rare. Patients with TDT may have altered immunity due to chronic transfusions, iron overload and chelation therapy, and splenic dysfunction. Here, we show that adult patients with TDT following vaccination with the novel messenger RNA vaccines have mild adverse events and can produce protective antibodies comparable to the healthy population.